| ANGIOCEPT ADNEXUS A BRISTOL-MYERS SQUIBB R&D COMPANY
(A DELAWARE CORPORATION)
1381354 30 Jan 2008 | on 21 Aug 2013 | Class 005 Class 005 Pharmaceutical Products Biotechnology and pharmaceutical products, namely, therapeutic proteins for human use for the treatment and prevention of obesity, diabetes, incontinence, cardiovascular diseases, metabolic disorders, stroke, cancer, auto-immune diseases, solid organ transplant rejection; pharmaceutical preparations for the treatment of the respiratory system; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, anti-inflammatories, anti-infectives, central nervous system depressants, central nervous system stimulants, anti-psychotics and pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories. | | 
